Figure 6From: 1’-Acetoxychavicol acetate inhibits growth of human oral carcinoma xenograft in mice and potentiates cisplatin effect via proinflammatory microenvironment alterations Reduction of tumor volumes when treated with ACA and CDDP in combination on Nu/Nu mice. (A) Photographs of Nu/Nu mice harvested 35 days post-implantation with human oral SCC (HSC-4) xenografts and 21 days post-treatment with various ACA/CDDP treatment regimes. Location of all tumor sites are indicated by closed arrows. (B) Representative photographs (n=5) of dissected oral tumors from different treatment regimes. (C) Tumor volume regression between various treatment groups 35 days post-implantation and 21 days post-treatment. (D) Assessment on body weight loss between various ACA/CDDP treatment groups. Data shown as mean value ± SEM of five replicates per group and 0.9% (w/v) sodium chloride solution was used in placebo groups. Statistically significant differences from placebo groups are shown by (*p ≤ 0.05) and (**p ≤ 0.1).Back to article page